08:36 AM EDT, 08/12/2024 (MT Newswires) -- Absci ( ABSI ) said Monday that it has partnered with Memorial Sloan Kettering Cancer Center to develop new therapeutics using generative AI across up to six programs.

Absci ( ABSI ) said the collaboration would leverage its Integrated Drug Creation platform and Memorial Sloan Kettering Cancer Center's expertise in cancer research.

Financial terms of the deal were not disclosed.

Price: 3.6100, Change: -0.08, Percent Change: -2.17